Relapses in multiple sclerosis can result in irreversible nervous system tissue injury. If these events could be detected early, targeted immunotherapy could potentially slow disease progression. We describe the use of engineered biomaterial-based immunological niches amenable to biopsy to provide insights into the phenotype of innate immune cells that control disease activity in a mouse model of multiple sclerosis. Differential gene expression in cells from these niches allow monitoring of disease dynamics and gauging the effectiveness of treatment. A proactive treatment regimen, given in response to signal within the niche but before symptoms appeared, substantially reduced disease. This technology offers a new approach to monitor organ-specific autoimmunity, and represents a platform to analyze immune dysfunction within otherwise inaccessible target tissues.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398910 | PMC |
| http://dx.doi.org/10.1038/s41467-020-17629-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Prospective memory, multiple sclerosis and ageing: assessment in a familiar context involving self-generated and imposed intentions].
Geriatr Psychol Neuropsychiatr Vieil
September 2024
Département de psychologie, Université du Québec à Montréal, Canada, Centre de recherche du centre hospitalier de l'université de Montréal, Canada.
Atypical Presentation of Optic Neuritis in Multiple Sclerosis.
Cureus
December 2024
Ophthalmology, Medical Teaching Institution (MTI) Khyber Teaching Hospital, Peshawar, PAK.
Optic neuritis (ON) is the inflammation of the optic nerve. 'Typical' ON is commonly associated with multiple sclerosis (MS) and its classic triad includes sudden loss of vision, pain with eye movement and dyschromatopsia. It usually has good visual outcome irrespective of treatment.
View Article and Find Full Text PDFExploring the shared gene signatures and mechanism among three autoimmune diseases by bulk RNA sequencing integrated with single-cell RNA sequencing analysis.
Front Mol Biosci
January 2025
Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Background: Emerging evidence underscores the comorbidity mechanisms among autoimmune diseases (AIDs), with innovative technologies such as single-cell RNA sequencing (scRNA-seq) significantly advancing the explorations in this field. This study aimed to investigate the shared genes among three AIDs-Multiple Sclerosis (MS), Systemic Lupus Erythematosus (SLE), and Rheumatoid Arthritis (RA) using bioinformatics databases, and to identify potential biomarkers for early diagnosis.
Methods: We retrieved transcriptomic data of MS, SLE, and RA patients from public databases.
Case report: Reversible splenial lesion syndrome preceding the onset of multiple sclerosis.
Front Immunol
January 2025
Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University and Centre for Cognitive Neuroscience, Salzburg, Austria.
Background: The reversible splenial lesion syndrome is frequently associated with systemic and central nervous system infections. Whether an infection associated with the occurrence of the reversible splenial lesion syndrome could play a role in the later development of multiple sclerosis is unknown.
Methods: Case Report.
Ligands of CD6: roles in the pathogenesis and treatment of cancer.
Front Immunol
January 2025
Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.
Cluster of Differentiation 6 (CD6), an established marker of T cells, has multiple and complex functions in regulation of T cell activation and proliferation, and in adhesion of T cells to antigen-presenting cells and epithelial cells in various organs and tissues. Early studies on CD6 demonstrated its role in mediating cell-cell interactions through its first ligand to be identified, CD166/ALCAM. The observation of CD6-dependent functions of T cells that could not be explained by interactions with CD166/ALCAM led to discovery of a second ligand, CD318/CDCP1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!